Skip to main content

Gritstone Oncology, Inc. (GRTS)

NASDAQ: GRTS · IEX Real-Time Price · USD
8.91
-0.02 (-0.22%)
After-hours:Oct 22, 2021 7:02 PM EDT
8.93
-0.10 (-1.11%)
At close: Oct 22, 4:00 PM
Market Cap580.19M
Revenue (ttm)44.82M
Net Income (ttm)-70.44M
Shares Out76.75M
EPS (ttm)-1.23
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume672,656
Open8.89
Previous Close9.03
Day's Range8.53 - 9.00
52-Week Range2.54 - 35.20
Beta0.09
AnalystsBuy
Price Target28.43 (+218.4%)
Est. Earnings DateNov 4, 2021

About GRTS

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types and infectious diseases. Its lead product candidate is GRANITE, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors, incl...

IndustryBiotechnology
IPO DateSep 28, 2018
CEOAndrew Allen
Employees181
Stock ExchangeNASDAQ
Ticker SymbolGRTS
Full Company Profile

Financial Performance

In 2020, GRTS's revenue was $4.04 million, a decrease of -7.51% compared to the previous year's $4.37 million. Losses were -$105.31 million, 11.5% more than in 2019.

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for GRTS stock is "Buy." The 12-month stock price forecast is 28.43, which is an increase of 218.37% from the latest price.

Price Target
$28.43
(218.37% upside)
Analyst Consensus: Buy

News

Does This Biotech Have the Secret to Conquering Covid Variants?

The company uses mRNA technology -- with a new twist.

Other symbols:AZNMRNAPFE
3 weeks ago - The Motley Fool

Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

EMERYVILLE, Calif., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunoth...

4 weeks ago - GlobeNewsWire

Gritstone Announces Dosing of First Volunteer in Trial Evaluating Self-Amplifying mRNA as a COVID-19 Vaccine Booster ...

GRT-R910, a self-amplifying mRNA (SAM) SARS-CoV-2 vaccine, delivers antigens from both the spike protein and highly conserved non-spike proteins for broad protection across variants

1 month ago - GlobeNewsWire

Gritstone Presents Data From Individualized Neoantigen Immunotherapy In Colorectal Cancer

Gritstone bio Inc (NASDAQ: GRTS) has announced updated results from the Phase 1/2 study of GRANITE individualized neoantigen immunotherapy in advanced solid tumors. The immunotherapy is a heterologous p...

1 month ago - Benzinga

Gritstone Announces Dosing of First Solid Tumor Patient with Optimized SLATE “Off-the-Shelf” Mutant KRAS-directed Neo...

EMERYVILLE, Calif., Sept. 17, 2021 (GLOBE NEWSWIRE) --  Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapie...

1 month ago - GlobeNewsWire

Gritstone Announces Private Placement Financing of $55.0 Million

EMERYVILLE, Calif., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies...

1 month ago - GlobeNewsWire

3 Explosive Biotech Stocks That Could 10X in 10 Years

They're leaders in therapeutic areas with massive growth potential.

Other symbols:BNTXCRSP
1 month ago - The Motley Fool

3 Monster Stocks in the Making to Buy Right Now

Their growth prospects are massive.

Other symbols:DMTKMTTR
1 month ago - The Motley Fool

Gritstone to Host Data Update on Neoantigen Oncology Programs for the Treatment of Solid Tumors During ESMO 2021

EMERYVILLE, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunoth...

1 month ago - GlobeNewsWire

Gritstone bio Inc. (GRTS) is a Great Momentum Stock: Should You Buy?

Does Gritstone bio Inc. (GRTS) have what it takes to be a top stock pick for momentum investors? Let's find out.

1 month ago - Zacks Investment Research

Gritstone Announces Presentations at Two Investor Conferences in September

EMERYVILLE, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunoth...

1 month ago - GlobeNewsWire

Gritstone (GRTS) Inks Deal With CEPI for Coronavirus Vaccine

Gritstone (GRTS) signs an agreement with CEPI for up to $20.6 million to develop its COVID-19 vaccine program with an initial focus in South Africa. Shares rise.

2 months ago - Zacks Investment Research

Gritsone Bio Secures CEPI Funding For Its Differentiated COVID-19 Vaccine Candidate

Gritstone bio Inc (NASDAQ: GRTS) has entered into a funding agreement of up to $20.6 million with the Coalition for Epidemic Preparedness Innovations (CEPI). The funding will support Gritstone's COVID-1...

2 months ago - Benzinga

Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

EMERYVILLE, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunothe...

2 months ago - GlobeNewsWire

Gritstone bio Inc. (GRTS) Reports Q2 Loss, Lags Revenue Estimates

Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of 37.74% and -5.23%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Gritstone Reports Second Quarter 2021 Financial Results and Business Update

EMERYVILLE, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies,...

2 months ago - GlobeNewsWire

Will Gritstone bio Inc. (GRTS) Report Negative Q2 Earnings? What You Should Know

Gritstone bio Inc. (GRTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Gritstone Announces Management Changes, Including the Appointment of Celia Economides as Chief Financial Officer

EMERYVILLE, Calif., June 23, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies,...

3 months ago - GlobeNewsWire

3 Top Biotech Picks for June

Coronavirus players may deliver strong returns well into the future.

Other symbols:RDHLVIR
4 months ago - The Motley Fool

Gritstone Announces Changes to Its Board of Directors

Drs. Naiyer A. Rizvi and Shefali Agarwal Join the Board Drs. Naiyer A. Rizvi and Shefali Agarwal Join the Board

4 months ago - GlobeNewsWire

Gritstone Oncology, Inc. (GRTS) Q1 Earnings and Revenues Top Estimates

Gritstone Oncology, Inc. (GRTS) delivered earnings and revenue surprises of 121.74% and 1223.10%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Gritstone Reports First Quarter 2021 Financial Results and Business Highlights

EMERYVILLE, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, ...

5 months ago - GlobeNewsWire

Gritstone Oncology Changes its Name to Gritstone bio to Reflect Expanded Therapeutic Focus

EMERYVILLE, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immun...

5 months ago - GlobeNewsWire

3 Top Coronavirus Stocks to Buy Right Now

Major gains may be on the horizon.

Other symbols:PFEREGN
5 months ago - The Motley Fool